Lianghui Zhang

The University of Illinois College of Medicine, Chicago, USA

Engineered ACE2 Decoy Mitigates Lung Injury and Death Induced by SARS-CoV-2 Variants

---

Biography

Dr. Zhang received her M.D. from Medical School of Fudan University and Ph.D. in Pharmacology from University of Rochester. Dr. Zhang’s research interests have been focused on exploring the mechanisms of inflammatory endothelial injury and repair using acute lung injury mouse model and developing novel mechanism-based regenerative strategies. Her scientific training began with her graduate work under the instruction of Dr. Alan Smrcka at the University of Rochester to dissect signal pathways of cardiac hypertrophy (Cell 2013).  Dr. Zhang’s postdoctoral training in lung vascular biology was with Dr. Jalees Rehman and Dr. Asrar Malik in the Department of Pharmacology at the University of Illinois at Chicago (Circulation 2017, Nature Communications 2019). Dr. Zhang started her own laboratory in 2021 with the funding support from NIH RO1. She  recently published the SARS-CoV-2 work in Nature Chemical Biology 2022.

Abstract

SARS-CoV-2, variants of concern, vascular biology, lung injury, peptide engineering, prophylactics, therapeutics